Literature DB >> 7546586

Serum antibodies to heat shock protein 70 in sensorineural hearing loss.

D B Bloch1, J E San Martin, S D Rauch, R A Moscicki, K J Bloch.   

Abstract

OBJECTIVE: To identify the 68-kd target of antibody in serum samples from patients with idiopathic, progressive, bilateral sensorineural hearing loss.
DESIGN: To purify target protein from renal extracts using gel filtration, ion-exchange chromatography, and polyacrylamide gel electrophoresis and to transfer to nitrocellulose membranes. The purified protein was digested with trypsin, and peptide fragments were separated by high-pressure liquid chromatography.
RESULTS: One fraction obtained by high-performance liquid chromatography contained a peptide of 2776 molecular weight. The sequence of a stretch of 22 amino acids within this peptide was identical to that of amino acids 424 through 445 of heat shock protein 70 (HSP70). On Western blotting, monoclonal antibody directed against HSP70 (but capable of recognizing both constitutive HSP70 [HSC70] and stress-inducible HSP70) reacted with the purified 68-kd protein. We compared the reactivity of serum samples from six patients with idiopathic, progressive, bilateral sensorineural hearing loss, as well as monoclonal antibody to HSC70, and monoclonal antibody to HSP70 with renal extract. The pattern obtained suggested that patient antibodies are preferentially directed at HSP70.
CONCLUSION: The target of antibody in serum samples from patients with idiopathic, progressive, bilateral sensorineural hearing loss is HSP70.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7546586     DOI: 10.1001/archotol.1995.01890100075013

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  10 in total

Review 1.  Antibodies against heat shock proteins in environmental stresses and diseases: friend or foe?

Authors:  Tangchun Wu; Robert M Tanguay
Journal:  Cell Stress Chaperones       Date:  2006       Impact factor: 3.667

Review 2.  New insights on biomarkers in systemic vasculitis.

Authors:  Rodolfo Perez-Alamino; Hernán Maldonado-Ficco
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

Review 3.  New prospects in the diagnosis and treatment of immune-mediated inner ear disease.

Authors:  David R Lobo; Jose Ramon García-Berrocal; Rafael Ramírez-Camacho
Journal:  World J Methodol       Date:  2014-06-26

4.  IL-1β inhibition in autoimmune inner ear disease: can you hear me now?

Authors:  Steven D Rauch
Journal:  J Clin Invest       Date:  2014-08-18       Impact factor: 14.808

Review 5.  Role of Inner Ear Macrophages and Autoimmune/Autoinflammatory Mechanisms in the Pathophysiology of Inner Ear Disease.

Authors:  Toru Miwa; Takayuki Okano
Journal:  Front Neurol       Date:  2022-04-06       Impact factor: 4.086

6.  Murine autoimmune hearing loss mediated by CD4+ T cells specific for inner ear peptides.

Authors:  C Arturo Solares; Andrea E Edling; Justin M Johnson; Moo-Jin Baek; Keiko Hirose; Gordon B Hughes; Vincent K Tuohy
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

7.  Autoantibodies to recombinant human CTL2 in autoimmune hearing loss.

Authors:  Pavan K Kommareddi; Thankam S Nair; Mounica Vallurupalli; Steven A Telian; H Alexander Arts; Hussam K El-Kashlan; Robert T Sataloff; Thomas E Carey
Journal:  Laryngoscope       Date:  2009-05       Impact factor: 3.325

Review 8.  The diagnosis of autoimmune inner ear disease: evidence and critical pitfalls.

Authors:  Roberto Bovo; Andrea Ciorba; Alessandro Martini
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-09-06       Impact factor: 2.503

Review 9.  Optimal management of Cogan's syndrome: a multidisciplinary approach.

Authors:  Vittorio D'Aguanno; Massimo Ralli; Marco de Vincentiis; Antonio Greco
Journal:  J Multidiscip Healthc       Date:  2017-12-22

Review 10.  The Role of Autoimmunity in the Pathogenesis of Sudden Sensorineural Hearing Loss.

Authors:  Guangfei Li; Dan You; Jiaoyao Ma; Wen Li; Huawei Li; Shan Sun
Journal:  Neural Plast       Date:  2018-06-13       Impact factor: 3.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.